Study of Angiogenic Markers to Guide Delivery Timing in Women with Preeclampsia at Term

What this Trial Is About

Researchers are evaluating the use of angiogenic markers sFlt-1PlGF ratio to manage delivery timing in women with preeclampsia without severe features between 36 and 386 weeks of pregnancy. The study aims to see if basing delivery decisions on these markers can reduce the need for labor induction without increasing the risk of developing severe preeclampsia or other maternal complications. This is an open-label, randomized controlled trial sponsored by Hospital Universitari Vall dHebron Research Institute. Participants are randomly assigned to one of two groups. In the intervention group, if angiogenic markers are normal sFlt-1PlGF <38, delivery is delayed until 39 weeks if abnormal sFlt-1PlGF 38, labor induction is recommended at or after 37 weeks. The control group receives the current standard care with elective delivery scheduled at 37 weeks. Both groups have NT-proBNP levels measured at enrollment, and delivery is immediately recommended if any urgent maternal or fetal conditions arise. During the study, participants complete satisfaction questionnaires at enrollment and four weeks postpartum. Researchers monitor maternal and neonatal outcomes, including complications, ICU admissions, gestational age at delivery, birthweight, and maternal NT-proBNP levels. The primary outcome is a composite of maternal health measures assessed through about two months after delivery. The study is expected to last until April 2028.

NOPE37: Angiogenic Factors for Managing Term Preeclampsia